AU2020281650B2 - Novel compounds and pharmaceutical compositions thereof for the treatment of diseases - Google Patents

Novel compounds and pharmaceutical compositions thereof for the treatment of diseases

Info

Publication number
AU2020281650B2
AU2020281650B2 AU2020281650A AU2020281650A AU2020281650B2 AU 2020281650 B2 AU2020281650 B2 AU 2020281650B2 AU 2020281650 A AU2020281650 A AU 2020281650A AU 2020281650 A AU2020281650 A AU 2020281650A AU 2020281650 B2 AU2020281650 B2 AU 2020281650B2
Authority
AU
Australia
Prior art keywords
independently selected
diseases
difluoromethoxy
methoxy
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020281650A
Other languages
English (en)
Other versions
AU2020281650A1 (en
Inventor
Luke Jonathan ALVEY
Florence Marie-Emilie Bonnaterre
Denis BUCHER
Nicolas Desroy
Béranger DUTHION
Hélène Marie JARY
Christophe Peixoto
Taoues TEMAL-LAÏB
Amynata TIRERA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Onco3r Therapeutics BV
Original Assignee
Onco3r Therapeutics BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onco3r Therapeutics BV filed Critical Onco3r Therapeutics BV
Publication of AU2020281650A1 publication Critical patent/AU2020281650A1/en
Assigned to ONCO3R THERAPEUTICS BV reassignment ONCO3R THERAPEUTICS BV Request for Assignment Assignors: GALAPAGOS NV
Application granted granted Critical
Publication of AU2020281650B2 publication Critical patent/AU2020281650B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2020281650A 2019-05-29 2020-05-25 Novel compounds and pharmaceutical compositions thereof for the treatment of diseases Active AU2020281650B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1907616.5A GB201907616D0 (en) 2019-05-29 2019-05-29 Novel compounds and pharmaceutical compositons thereof for the treatment of diseases
GB1907616.5 2019-05-29
PCT/EP2020/064368 WO2020239658A1 (en) 2019-05-29 2020-05-25 Novel compounds and pharmaceutical compositions thereof for the treatment of diseases

Publications (2)

Publication Number Publication Date
AU2020281650A1 AU2020281650A1 (en) 2022-02-03
AU2020281650B2 true AU2020281650B2 (en) 2025-08-28

Family

ID=67385363

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020281650A Active AU2020281650B2 (en) 2019-05-29 2020-05-25 Novel compounds and pharmaceutical compositions thereof for the treatment of diseases

Country Status (26)

Country Link
US (1) US12391679B2 (enExample)
EP (1) EP3976189B1 (enExample)
JP (1) JP7550174B2 (enExample)
KR (1) KR20220015450A (enExample)
CN (1) CN113924146B (enExample)
AR (1) AR119028A1 (enExample)
AU (1) AU2020281650B2 (enExample)
BR (1) BR112021023900A2 (enExample)
CA (1) CA3141683A1 (enExample)
CL (1) CL2021003133A1 (enExample)
CO (1) CO2021017656A2 (enExample)
CR (1) CR20210586A (enExample)
DO (1) DOP2021000227A (enExample)
EA (1) EA202193281A1 (enExample)
ES (1) ES2985528T3 (enExample)
GB (1) GB201907616D0 (enExample)
IL (1) IL288375B1 (enExample)
MA (1) MA56019A (enExample)
MX (1) MX2021013803A (enExample)
PE (1) PE20220503A1 (enExample)
PH (1) PH12021552691A1 (enExample)
PL (1) PL3976189T3 (enExample)
SG (1) SG11202112652RA (enExample)
TW (1) TW202110839A (enExample)
WO (1) WO2020239658A1 (enExample)
ZA (1) ZA202110597B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11241435B2 (en) 2016-09-16 2022-02-08 The General Hospital Corporation Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis
US11149009B2 (en) 2019-03-11 2021-10-19 Inflarx Gmbh Fused piperidinyl bicyclic and related compounds as modulators of C5A receptor
GB201907558D0 (en) * 2019-05-29 2019-07-10 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
IL300205A (en) * 2020-08-05 2023-03-01 Massachusetts Gen Hospital Salt-inducible kinase inhibitors
USD982434S1 (en) * 2021-08-31 2023-04-04 Level Up Dice LLC Dice storage container
WO2023066204A1 (zh) * 2021-10-18 2023-04-27 上海美悦生物科技发展有限公司 Sik抑制剂及其组合物、制备方法和用途
AR128279A1 (es) * 2022-01-19 2024-04-10 Hoffmann La Roche Nuevos derivados de bencimidazol piridina
CN115304605B (zh) * 2022-01-21 2023-10-03 陕西国际商贸学院 具有抗肿瘤活性的氧杂环丁烷衍生物及其制备方法和应用
CN119451959A (zh) * 2022-07-01 2025-02-14 豪夫迈·罗氏有限公司 咪唑并[4,5-c]吡啶衍生物作为sik调节剂用于类风湿性关节炎的治疗
US20240124450A1 (en) * 2022-09-21 2024-04-18 Pfizer Inc. Novel SIK Inhibitors
CN120239700A (zh) * 2022-11-17 2025-07-01 英矽智能科技知识产权有限公司 盐诱导激酶(sik)抑制剂及其使用方法
TW202509021A (zh) * 2023-05-24 2025-03-01 日商田邊三菱製藥股份有限公司 鹽誘導之激酶抑制化合物以及包含其之醫藥組成物
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用
AR133277A1 (es) * 2023-07-19 2025-09-10 Hoffmann La Roche Nuevos derivados de bencimidazol piridina
WO2025068090A1 (en) * 2023-09-26 2025-04-03 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of diseases
WO2025232877A1 (en) * 2024-05-10 2025-11-13 Insilico Medicine Ip Limited Salt-inducible kinases (sik) inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014093383A1 (en) * 2012-12-14 2014-06-19 Arrien Pharmaceuticals Llc Substituted 1h-pyrrolo [2,3-b] pyridine and 1h-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (sik2) inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2178375B1 (en) 2007-07-20 2014-09-24 Merck Sharp & Dohme Corp. Pyrazoloý1,5-a¨pyrimidine derivatives
US20140243324A1 (en) * 2010-11-18 2014-08-28 Ligand Pharmaceuticals Incorporated Use of hematopoietic growth factor mimetics
KR20140018852A (ko) 2010-12-01 2014-02-13 플라산 카본 컴포짓, 인코포레이티드 복합 물품을 형성하는 방법과 시스템
EP2825540B1 (en) * 2012-03-14 2016-09-14 Bayer Intellectual Property GmbH Substituted imidazopyridazines
AU2016315881B2 (en) 2015-09-03 2019-09-19 The Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK1A and uses thereof
CN106496222A (zh) 2016-09-07 2017-03-15 华东师范大学 一种咪唑并[1,2‑a]吡啶化合物及其制备方法和应用
HUE057581T2 (hu) 2017-12-02 2022-05-28 Galapagos Nv Új vegyületek és ezeket tartalmazó gyógyszerkészítmények betegségek kezelésére
CN108358894B (zh) * 2018-04-26 2021-05-07 四川大学 一种抑制组蛋白乙酰转移酶的化合物及其制备方法与应用
CN118359612A (zh) 2018-06-15 2024-07-19 加拉帕戈斯股份有限公司 用于治疗疾病的化合物及其药物组合物
CN118684661A (zh) 2023-03-21 2024-09-24 上海美悦生物科技发展有限公司 杂芳基类化合物及其药物组合物、制备方法和用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014093383A1 (en) * 2012-12-14 2014-06-19 Arrien Pharmaceuticals Llc Substituted 1h-pyrrolo [2,3-b] pyridine and 1h-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (sik2) inhibitors

Also Published As

Publication number Publication date
MX2021013803A (es) 2021-12-14
MA56019A (fr) 2022-04-06
IL288375B1 (en) 2025-09-01
CR20210586A (es) 2022-01-24
PH12021552691A1 (en) 2022-03-14
TW202110839A (zh) 2021-03-16
AR119028A1 (es) 2021-11-17
EP3976189A1 (en) 2022-04-06
JP2022534578A (ja) 2022-08-02
KR20220015450A (ko) 2022-02-08
DOP2021000227A (es) 2022-05-15
PE20220503A1 (es) 2022-04-07
CL2021003133A1 (es) 2022-07-22
ES2985528T3 (es) 2024-11-06
CN113924146B (zh) 2024-12-10
BR112021023900A2 (pt) 2022-01-18
EP3976189B1 (en) 2024-07-03
CN113924146A (zh) 2022-01-11
GB201907616D0 (en) 2019-07-10
WO2020239658A1 (en) 2020-12-03
CO2021017656A2 (es) 2022-01-17
PL3976189T3 (pl) 2024-09-09
SG11202112652RA (en) 2021-12-30
AU2020281650A1 (en) 2022-02-03
ZA202110597B (en) 2024-10-30
IL288375A (en) 2022-01-01
JP7550174B2 (ja) 2024-09-12
US12391679B2 (en) 2025-08-19
CA3141683A1 (en) 2020-12-03
EP3976189C0 (en) 2024-07-03
US20220340548A1 (en) 2022-10-27
EA202193281A1 (ru) 2022-03-01

Similar Documents

Publication Publication Date Title
AU2020281650B2 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
US12065443B2 (en) Compounds and pharmaceutical compositions thereof for the treatment of diseases
KR102758615B1 (ko) 질병의 치료를 위한 신규 화합물 및 그의 약학 조성물
TWI866258B (zh) 用於治療發炎性病症之新穎化合物及其醫藥組合物
JP7621277B2 (ja) 疾患の治療のための新規化合物及びその医薬組成物
HK40072732A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
HK40072732B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
RU2782375C2 (ru) Новые соединения и их фармацевтические композиции для лечения заболеваний
TW202515881A (zh) 用於治療疾病之化合物及其醫藥組合物
HK40037090B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ONCO3R THERAPEUTICS BV

Free format text: FORMER APPLICANT(S): GALAPAGOS NV